There is a high unmet clinical need for effective antifibrotic therapies in systemic sclerosis (SSc), and in parallel a rapid development in the identification of potential molecular targets in preclinical research. This could increase the possibility to develop successful drugs against the fibrotic manifestations of SSc. PubMed, Curr Opin Rheumatol. 2013 Nov;25(6):679-85. (Also see: What is Fibrosis? and Scleroderma Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.